The answers to common questions that you may have about the registry are below. If you do not see the answer to your specific question here, please contact us at ocrevuspregnancyregistry@iqvia.com or use the registry’s toll-free number 1 (833) 872-4370.
This is a global registry for women with MS who are 18 years or older, pregnant, and have or have not received OCREVUS® (ocrelizumab). The purpose of this pregnancy registry is to learn more about the health of pregnant women who have received ocrelizumab and the health of their babies, compared with those who have not. This will be done by monitoring participants throughout their pregnancy, then monitoring the health of their babies until they are at least 12 months old.
You will be contacted when you join the registry, and then once during each trimester of your pregnancy. After you have given birth, you will be contacted when your baby is 1, 3, 6, and 12 months old. Your healthcare providers will also be contacted twice during your pregnancy, and approximately 4 weeks after your estimated delivery date. Your baby’s healthcare provider will be contacted when your baby is 1, 3, 6, and 12 months old. You will not be asked to attend extra visits at a healthcare provider’s office, change anything you usually do, or change any treatments that you currently receive for the duration of your participation in the registry.
After you decide that you want to join the registry and give your informed consent, you will need to answer a few questions to see if you are eligible for participation.
If you are eligible to take part, you will be asked to provide some information about yourself, your health and your pregnancy, and will be contacted once during each trimester of your pregnancy. After you have given birth, you will be contacted when your baby is 1, 3, 6, and 12 months old. Your healthcare providers will also be contacted twice during your pregnancy, and within 4 weeks of your estimated delivery date. Your baby’s healthcare provider will be contacted when your baby is 1, 3, 6, and 12 months old.
You will not be asked to attend extra visits at a healthcare provider’s office, change anything you usually do, or change any treatments that you currently receive for the duration of your participation in the registry.
We will use your information for research purposes. We will collect information about your identity, health, and the health of your baby. The information you provide may help researchers gain insight into the use of ocrelizumab during pregnancy.
The information you provide in telephone interviews will not be associated with your name, your baby’s name, or your contact details. Your personally identifying information will not be shared with F. Hoffman-La Roche Ltd, the Sponsor of this registry. In any presentation of results from this registry, your identity will remain anonymous and confidential. The information will be deleted from the IQVIA database at completion of the registry.
For the latest important safety information, please refer to the full Prescribing Information and Medication Guide. This is not intended to replace discussions with healthcare providers.
This site uses cookies including for the essential functioning of the site and for analytical purposes. For more information about these cookies and the choices you have to manage them, please view our Privacy Policy or visit the Interactive Advertising Bureau
By clicking through the website, we understand this means you have accepted our cookies.